Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 382
- Registration Number
- NCT03148418
- Locations
- 🇫🇷
GH Paris Saint Joseph, Paris, France
🇨🇿Masarykuv onkologicky ustav, Brno, Czechia
🇨🇿Thomayerova nemocnice, Praha 4 - Krc, Czechia
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03139513
- Locations
- 🇫🇷
CH Metropole de Savoie, CHAMBERY Cedex, France
🇫🇷Hopital Louis Pasteur; Sce Dermatologie, Colmar, France
🇫🇷Hopital Cochin; Dermatologie, Paris, France
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Follicular LymphomaLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03135262
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 653
- Registration Number
- NCT03125902
- Locations
- 🇺🇸
Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States
🇨🇿Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia
🇸🇰Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A, Bratislava, Slovakia
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 806
- Registration Number
- NCT03114657
- Locations
- 🇺🇸
Texas Neurology PA, Dallas, Texas, United States
🇮🇹Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy
🇪🇸Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain
Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT03115619
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology, Athens, Greece
🇬🇷University General Hospital of Athens "Attikon", B' University Pulmonary Clinic, Chaidari, Greece
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT03112213
- Locations
- 🇩🇪
Praxis Prof. Dr.med. Herbert Kellner, München, Germany
🇩🇪Rheumazentrum Kupka, Altenburg, Germany
🇩🇪Praxis für Rheumatologie., Amberg, Germany
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03101280
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸La Paz University Hospital, Madrid, Spain
🇫🇷Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale, Pierre Benite, France
Compare Bioavailability of RO7239361 After Subcutaneous Injection
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT03100630
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Other: No Intervention
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT03099200
- Locations
- 🇬🇧
Nevill Hall Hospital, Abergavenny, United Kingdom
🇬🇧Royal Devon & Exeter Hospital; Oncology Centre, Exeter, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom